Cargando…

The long journey to bring a Myc inhibitor to the clinic

The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically d...

Descripción completa

Detalles Bibliográficos
Autores principales: Whitfield, Jonathan R., Soucek, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Rockefeller University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240852/
https://www.ncbi.nlm.nih.gov/pubmed/34160558
http://dx.doi.org/10.1083/jcb.202103090
_version_ 1783715286315171840
author Whitfield, Jonathan R.
Soucek, Laura
author_facet Whitfield, Jonathan R.
Soucek, Laura
author_sort Whitfield, Jonathan R.
collection PubMed
description The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable.
format Online
Article
Text
id pubmed-8240852
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-82408522022-02-02 The long journey to bring a Myc inhibitor to the clinic Whitfield, Jonathan R. Soucek, Laura J Cell Biol Perspective The oncogene Myc is deregulated in the majority of human tumors and drives numerous hallmarks of cancer. Despite its indisputable role in cancer development and maintenance, Myc is still undrugged. Developing a clinical inhibitor for Myc has been particularly challenging owing to its intrinsically disordered nature and lack of a binding pocket, coupled with concerns regarding potentially deleterious side effects in normal proliferating tissues. However, major breakthroughs in the development of Myc inhibitors have arisen in the last couple of years. Notably, the direct Myc inhibitor that we developed has just entered clinical trials. Celebrating this milestone, with this Perspective, we pay homage to the different strategies developed so far against Myc and all of the researchers focused on developing treatments for a target long deemed undruggable. Rockefeller University Press 2021-06-23 /pmc/articles/PMC8240852/ /pubmed/34160558 http://dx.doi.org/10.1083/jcb.202103090 Text en © 2021 Whitfield and Soucek http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Perspective
Whitfield, Jonathan R.
Soucek, Laura
The long journey to bring a Myc inhibitor to the clinic
title The long journey to bring a Myc inhibitor to the clinic
title_full The long journey to bring a Myc inhibitor to the clinic
title_fullStr The long journey to bring a Myc inhibitor to the clinic
title_full_unstemmed The long journey to bring a Myc inhibitor to the clinic
title_short The long journey to bring a Myc inhibitor to the clinic
title_sort long journey to bring a myc inhibitor to the clinic
topic Perspective
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8240852/
https://www.ncbi.nlm.nih.gov/pubmed/34160558
http://dx.doi.org/10.1083/jcb.202103090
work_keys_str_mv AT whitfieldjonathanr thelongjourneytobringamycinhibitortotheclinic
AT souceklaura thelongjourneytobringamycinhibitortotheclinic
AT whitfieldjonathanr longjourneytobringamycinhibitortotheclinic
AT souceklaura longjourneytobringamycinhibitortotheclinic